Can Adagrasib be purchased in domestic hospitals?

Adagrasib has not yet been officially launched in China, so patients cannot directly purchase the drug in domestic hospitals. Adagrasiib is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. It is an important targeted therapy drug. However, the drug is not currently approved for sale in China, forcing patients who need it to obtain it through other means.

Although adagrasib is not yet available in China, patients can still purchase the drug through overseas channels. Common purchasing channels include cross-border e-commerce platforms, overseas drug suppliers, and obtaining drugs through patients and pharmaceutical intermediary channels. It should be noted that there may be certain risks in purchasing drugs across borders, such as drug authenticity issues, customs restrictions, etc. Therefore, patients should carefully choose legal suppliers and channels.

The price of the original American version of adagrasib is relatively high, with the price of a box reaching more than 100,000 yuan. The price is a heavy burden for most patients. Despite this, due to its significant advantages in treating KRAS G12C mutated lung cancer, some patients still choose to purchase it abroad. However, with such high costs, many patients are looking for more affordable options.

In contrast, the prices of foreign generic drugs are more affordable. Take the generic drug of adagrasibu produced in Laos as an example, the price is about more than 3,000 yuan. The ingredients of this generic drug are basically the same as those of the original drug, and the efficacy is also similar. It is an important reference for many patients in drug selection. Although the price of generic drugs is relatively low, patients still need to choose channels carefully and consult their doctors to ensure the quality and efficacy of the drugs.

References：https://www.krazati.com/